my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
31-10-2005: Avecia announced that it has signed a definitive agreement to sell its Pharmaceutical custom synthesis business to Nicholas Piramal India Ltd for GBP 9.5 million. The transaction, which will fund the business' UK pension fund deficit of between GBP 8 - 9 m, is subject to regulatory and other closing conditions. In 2004, the business recorded sales of GBP 36 million.
The sale includes all Avecia Pharmaceuticals' assets and operations at its principal UK site in Huddersfield, England, a large scale fermentation asset at Billingham, England, a High Potency Substance (HPS) facility at Grangemouth in Scotland and its North American operation - Torcan Chemicals in Aurora, Canada. All 350 Avecia Pharmaceuticals' employees are included in the transaction.
David Killworth, Vice President Avecia Pharmaceuticals said: "I am delighted that we will be joining forces with Nicholas Piramal India Ltd to create a major new force in the custom synthesis business. This transaction brings together the strengths of Indian and Western operations to provide a total lifecycle solution which addresses the changing requirements of the global pharmaceutical and biotechnology sectors".
Watchlist
This is where you can add this news to your personal favourites
A multi-disciplinary UK consortium of partners including Avecia, Intertek ASG, Lonza, Paraytec and the University of Bradford has recently been awarded research grants by the Technology Strategy Board and the Engineering and Physical Sciences Research Council. The part funded £1M+ project i ... more
Avecia completes sale of its Electronic Materials businesses
Avecia announced that it has completed the sale of its Electronic Materials businesses (Ink jet and Electrophotography) to FUJIFILM, having obtained all necessary approvals. This successfully concludes a sale agreement previously announced on 26th December 2005. The disposal includes all A ... more
Avecia completes sales of its Pharmaceuticals business unit
Avecia announced that it has completed the sale of its Pharmaceuticals custom synthesis business to Nicholas Piramal India Limited (NPIL), having obtained all necessary approvals. This successfully concludes a sale agreement previously announced on 27th October 2005. NPIL has paid GBP 9.5 ... more
Avecia completes sales of its Pharmaceuticals business unit
Avecia announced that it has completed the sale of its Pharmaceuticals custom synthesis business to Nicholas Piramal India Limited (NPIL), having obtained all necessary approvals. This successfully concludes a sale agreement previously announced on 27th October 2005. NPIL has paid GBP 9.5 ... more
Avecia sells Pharmaceuticals business unit to Nicholas Piramal India Ltd
Avecia announced that it has signed a definitive agreement to sell its Pharmaceutical custom synthesis business to Nicholas Piramal India Ltd for GBP 9.5 million. The transaction, which will fund the business' UK pension fund deficit of between GBP 8 - 9 m, is subject to regulatory and othe ... more
Rhodia divests its Anaesthetics Business to Nicholas Piramal India Ltd
Rhodia announced it has signed an agreement for the sale of its anaesthetics business to Nicholas Piramal India Ltd. Based at its Avonmouth UK production site, the business manufactures Halothane and Isoflurane, inhalation anaesthetics which are sold globally. Production assets are not in ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
